Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | RORC | P51449 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837961 | 0.91 | P2RX7 (0.40) | TRPA1RORCKMT2AALDH1A1CYP3A4 | |
| SCHEMBL4836571 | 0.90 | TRPA1 (0.40) | TRPA1RORCLMNAKMT2AMMP8 | |
| SCHEMBL4843317 | 0.90 | TRPA1 (0.45) | TRPA1RORCMMP8MMP3 | |
| SCHEMBL4839704 | 0.89 | TRPA1 (0.42) | TRPA1RORCLMNAMMP8MMP3 | |
| SCHEMBL4845053 | 0.89 | TRPA1 (0.42) | TRPA1RORCLMNAMMP8MMP3 | |
| SCHEMBL4035280 | 0.87 | LMNA (0.49) | TRPA1RORCLMNAMMP8MMP3 | |
| SCHEMBL4845190 | 0.87 | TRPA1 (0.44) | TRPA1RORCMMP8MMP3 | |
| SCHEMBL4843226 | 0.86 | TRPA1 (0.43) | TRPA1RORCMMP8MMP3 | |
| SCHEMBL4833515 | 0.86 | RORC (0.37) | TRPA1RORCLMNAKMT2AALDH1A1 | |
| SCHEMBL4039610 | 0.85 | RAB9A (0.47) | TRPA1RORCLMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | TRPA1 368/4885RORC 1777/4885LMNA 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.